Gastric Cancer, Gastric Cancer (Diagnosis), Gastric (Stomach) Cancer
Conditions
Keywords
Gastric Cancer, Gastric cancer in Algerian patients, Observational study, Patient outcomes, Oncology, Retrospective data, Treatment strategies, Diagnostic approaches, Clinical characteristics, Epidemiological data, Demographic data, Cross-sectional study, Real-world data, Algeria, Algerian Study
Brief summary
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Detailed description
This is a non-interventional, observational, descriptive, cross-sectional clinical study with both prospective and retrospective data collection. It aims to describe the demographic, epidemiological, clinical, and outcome characteristics of approximately 1,000 patients with histologically confirmed gastric cancer in Algeria, and to analyze diagnostic and treatment practices. Data will be collected from medical records and brief patient interviews (≈30 minutes). All information will be anonymized and used exclusively for research purposes.
Interventions
None listed
Sponsors
Société Algérienne de Formation et Recherche en Oncologie
Bristol-Myers Squibb
ES Clinical Research
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 19 years and older * Histologically confirmed diagnosis of gastric cancer * Patients followed in the participating oncology departments * Informed consent obtained Non Inclusion Criteria: * Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.). * Secondary gastric tumors * Participation in an interventional study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics of patients with gastric cancer in Algeria | At Baseline ( Initial visit ) | The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²). |
| Sociological characteristics of patients with gastric cancer in Algeria | At Baseline ( Initial visit ) | The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin) |
| Epidemiological characteristics of patients with gastric cancer in Algeria. | At Baseline (Initial Visit) | Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances. |
| Clinical characteristics of patients with gastric cancer in Algeria. | At Basline ( Initial Visit) | Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification. |
| Evolutionary characteristics of patients with gastric cancer. | At Baseline ( Initial Visit) | Distribution of treatment modalities including surgery (palliative or curative) and chemotherapy (adjuvant or treatment lines), as well as treatment response, complications, disease-free survival (DFS), and duration of response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic modalities in patients with gastric cancer in Algeria | At Basline (Initial Visit) | Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis. |
| Therapeutic management modalities | At Baseline (Initial Visit) | Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up. |
Countries
Algeria
Outcome results
None listed